adalimumab
Last reviewed 01/2018
- adalimumab is a human-sequence antibody that binds specifically to TNF-alpha
and neutralises its biological function by blocking its interaction with cell-surface
TNF-alpha receptors
- adalimumab also modulates biological responses that are induced or regulated by TNF-alpha, including changes in the levels of adhesion molecules responsible for leukocyte migration
- the summary of product characteristics (SPC) states that adalimumab should be given in combination with methotrexate, except where methotrexate is not tolerated or is considered inappropriate
-
common adverse events reported during adalimumab therapy include injection-site
reactions and infections
- before initiation of therapy, all patients must be evaluated for both active and inactive (latent) tuberculosis infection
- adalimumab is contraindicated in patients with moderate to severe heart failure, active tuberculosis or other active infections
For full details of side effects and contraindications, see the SPC.
Reference: